GenSight Biologics S.A. (EPA:SIGHT)
France
· Delayed Price · Currency is EUR 0.0917
-0.0011 (-1.19%)
Mar 6, 2026, 1:00 PM CET
GenSight Biologics Employees
GenSight Biologics had 13 employees as of June 30, 2025. The number of employees decreased by 3 or -18.75% since the number was reported on December 31, 2024.
Employees
13
Change
-3
Growth
-18.75%
Revenue / Employee
€72,692
Profits / Employee
€1,163,077
Market Cap
20.46M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| genOway Société anonyme | 148 |
| Aelis Farma | 24 |
| Advicenne | 13 |
| NFL Biosciences | 5 |
| Poxel | 5 |
| Oncodesign Precision Medicine Société anonyme | 14 |
| Fermentalg | 63 |
| Nicox | 5 |
GenSight Biologics News
- 16 days ago - GenSight Biologics Bolsters Regulatory Leadership in US and Europe with Two Senior Appointments - Business Wire
- 24 days ago - The 15-20 National Hospital and GenSight Biologics Announce the Treatment of the First Patient in the GS010/LUMEVOQ® REVISE Study - Business Wire
- 5 weeks ago - GenSight Biologics Announces the Results of its Extraordinary General Meeting of January 28, 2026 - Business Wire
- 2 months ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire
- 2 months ago - GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - Business Wire
- 2 months ago - GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France - Business Wire
- 3 months ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire
- 4 months ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire